Información del artículo
El Texto completo está disponible en PDF
References
[1.]
S.M. Haffner, S. Lehto, T. Rönnemaa, K. Pyörälä, M. Laakso.
Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction.
N Engl J Med, 339 (1998), pp. 229-234
[2.]
M. Laakso, S. Lehto.
Epidemiology of macrovascular disease in diabetes.
Diabetes Rev, 5 (1997), pp. 294-315
[3.]
M. Laakso.
Epidemiology of diabetic dyslipidemia.
Diabetes Rev, 3 (1995), pp. 408-422
[4.]
T. Mazzone, A. Chait, J. Plutzky.
Cardiovascular disease risk in type 2 diabetes mellitus: insights from mechanistic studies.
Lancet, 371 (2008), pp. 1800-1809
[5.]
R.C. Turner, H. Millns, H.A. Neil, I.M. Stratton, S.E. Manley, D.R. Matthews, et al.
for the United Kingdom Prospective Diabetes Study Group. Risk factors for coronary artery disease in noninsulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS 23).
BMJ, 316 (1998), pp. 823-828
[6.]
S. Lehto, T. Rönnemaa, S.M. Haffner, K. Pyörälä, V. Kallio, M. Laakso.
Dyslipidemia and hyperglycemia predict coronary heart disease events in middle-aged patients with NIDDM.
Diabetes, 48 (1997), pp. 1354-1359
[7.]
M. Adiels, S.O. Olofsson, M.R. Taskinen, J. Boren.
Overproductionof very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome.
Arterioscler Thomb Vasc Biol, 28 (2008), pp. 1225-1236
[8.]
M. Adiels, M.R. Taskinen, C. Packard, M.J. Caslake, A. Soro-Paavonen, J. Westerbacka, et al.
Overproduction of large VLDL particles is driven by increased liver fat content in man.
Diabetologia, 49 (2006), pp. 755-765
[9.]
M.A. Austin, M-.C. King, K.M. Vranizan, R.M. Krauss.
Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk.
Circulation, 82 (1990), pp. 495-506
[10.]
C. Baigent, A. Keech, P.M. Kearney, L. Blackwell, G. Buck, C. Pollicino, for Cholesterol Treatment Trialists’ (CTT) Collaborators, et al.
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins.
Lancet, 366 (2005), pp. 1267-1278
[11.]
P.M. Kearney, L. Blackwell, R. Collins, A. Keech, R. Simes, R. Peto, For the Cholesterol Treatment Trialists’ (CTT) Collaborators, et al.
Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis.
Lancet, 371 (2008), pp. 117-125
[12.]
A. Keech, R.J. Simes, P. Barter, J. Best, R. Scott, M.R. Taskinen, et al.
Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.
Lancet, 366 (2005), pp. 1849-1861
Copyright © 2009. Sociedad Española de Endocrinología y Nutrición